Department of Endocrinology, Acibadem University School of Medicine, Istanbul, Turkey.
Department of Medical Biotechnology, Acibadem University, Istanbul, Turkey.
Br J Neurosurg. 2024 Apr;38(2):486-492. doi: 10.1080/02688697.2021.1903388. Epub 2021 Apr 1.
Gamma knife radiosurgery (GKRS) is an established treatment option for residual and recurrent nonfunctioning pituitary adenoma (NFPA). This investigation assessed hormonal and radiologic outcomes after adjuvant and primary GKRS for NFPAs.
This retrospective study included 252 patients with NFPA who underwent GKRS at a single center between 2005 and 2016. GKRS was performed as adjuvant procedure in 216 (85.8%) patients and as primary procedure in 36 (14.2%) patients. Characteristics of these two groups were compared.
Mean age was comparable between adjuvant and primary GKRS groups (48.3 ± 12.6 vs. 52.2 ± 13.2 years, respectively, 0.05). Adjuvant GKRS and primary GKRS groups were similar in terms of the mean prescribed radiation dose and tumor volume (15.1 ± 2.7 vs. 15.3 ± 1.9 Gy and 4.2 ± 3.6 vs. 3.1 ± 2.5 cm, respectively, 0.05 for both). The rate of endocrine deficiency during 5-year follow-up showed similar trend in adjuvant and primary GKRS groups (3.7%, 8.7%, and 14.8% vs. 5.6%, 13.9%, and 27.8% at first, third, and fifth year time points, respectively). Tumor control rates were also similar (98.6%, 96.3%, and 93% vs. 100%, 97.3%, and 94.5% at first, third, and fifth year time points, respectively). In both groups, tumor volume >5 cm was associated with higher rate of hypopituitarism and tumor progression.
GKRS was effective both as adjuvant and primary procedure in patients with NFPA. Radiation dose of ≤13.5 Gy was associated with lower tumor control rate and tumor volume >5 cm was associated with higher rates of hypopituitarism and tumor progression.
伽玛刀放射外科(GKRS)是治疗残留和复发性无功能垂体腺瘤(NFPA)的一种成熟的治疗选择。本研究评估了辅助和原发性 GKRS 治疗 NFPA 的激素和影像学结果。
这项回顾性研究纳入了 2005 年至 2016 年期间在一家中心接受 GKRS 治疗的 252 例 NFPA 患者。216 例(85.8%)患者接受了辅助 GKRS,36 例(14.2%)患者接受了原发性 GKRS。比较了这两组患者的特征。
辅助 GKRS 和原发性 GKRS 组的平均年龄相似(分别为 48.3±12.6 岁和 52.2±13.2 岁,P=0.05)。辅助 GKRS 和原发性 GKRS 组的平均处方剂量和肿瘤体积也相似(分别为 15.1±2.7Gy 和 15.3±1.9Gy,4.2±3.6cm 和 3.1±2.5cm,P=0.05)。5 年随访期间内分泌缺乏的发生率在辅助 GKRS 和原发性 GKRS 组中呈相似趋势(第 1、3 和 5 年分别为 3.7%、8.7%和 14.8%;5.6%、13.9%和 27.8%)。肿瘤控制率也相似(第 1、3 和 5 年分别为 98.6%、96.3%和 93%;100%、97.3%和 94.5%)。在两组中,肿瘤体积>5cm 与更高的垂体功能减退和肿瘤进展发生率相关。
GKRS 对 NFPA 患者作为辅助和原发性治疗均有效。剂量≤13.5Gy 与较低的肿瘤控制率相关,肿瘤体积>5cm 与更高的垂体功能减退和肿瘤进展发生率相关。